Extended survival after chemotherapy and conservative radiotherapy for HPV-16 positive stage IVB oropharyngeal carcinoma

Abstract

Willemsen AECAB , van Herpen CML . mTOR inhibitor [1] related pulmonary toxicity; incidence even higher . Acta Oncol Epub 2013 Feb 14 . Iacovelli R , Palazzo A , Mezi S , Morano F , Naso G , Cortesi E . [2] Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy . A meta-analysis of published trials. Acta Oncol 2012 ; 51 : 873 – 9 . the RR was 10.5 (95% CI 2.9 – 37.8; p 0.001) and no heterogeneity was found (Q 0.1, p 0.99; I 2 0%) (Figure 1b). We performed a sensitivity analysis to test the effect of control on RR and we found greater RR in trials comparing mTORi with the placebo (RR: 51.6; 95% CI 7.2 – 369.1; p 0.001) compared to trials using active controls (RR: 30.4; 95% CI 5.9 – 155.2; p 0.001) for all grades of PT. However, considering the overlap of confi dence intervals these differences cannot be considered signifi cant. Similarly, differences were not found for high grade PT in placebo versus active controls (RR: 10.7 vs. 10.3, respectively). These data confi rmed our conclusion and those reported by Willemsen and van Herpen that patients treated with mTOR inhibitors have an increased risk Figure 1. Relative risk for all grades (a) or high grade (b) pulmonary toxicity in patients treated with mTOR inhibitors compared to controls.